This presentation is intended as an introductory overview of current industry best practices for minimizing the risk of non-sterile drug product contamination during the manufacturing process. A brief overview of the primary regulatory requirements and industry standards will be presented, (FDA, EU, ISO, ICH, USP, PDA, USP), followed by presentation and analysis of 3 differing approaches for contamination control, as derived from FDA, ISO, and USP.
Course Objectives:
Until recently, microbiological control strategies for non-sterile and sterile drugs alike have remained static, despite major technological and regulatory changes in the pharmaceutical industry. Compendial methods and limits have essentially been harmonized during the last 20 years, and there is now an array of rapid and real-time measurement technologies available to the QC microbiologist. However, today’s strategies for collecting and using microbiological data to demonstrate the state of bioburden control vary by industry and regulatory source. Additionally, these strategies are not fully aligned with the practical interests of the pharmaceutical industry, namely cost, time, and value. This training module discusses 3 of the primary microbiological control strategies for establishing and demonstrating appropriate contamination controls for non-sterile drug products and explains their origins and the differences between them.
Course Outline:
At the end of this training module, the participants should be able to
• Identify the current key regulatory and industry sources driving non-sterile drug contamination control programs
• Understand the 3 industry-based contamination control strategies, their origins, and differences
What You Get:
• Training Materials
• Live Q&A Session with our Expert
• Participation Certificate
• Access to Signup Community (Optional)
• Reward Points
Who Will Benefit:
This introductory-level course is designed for beginning and junior QC microbiologists, as well as non-microbiologist technical practitioners, such as engineering and operations staff involved in manufacturing, facility, and utility support and process design.
Packaging and Labeling for Commercial and Clinical Products
Get Instant Access 90 Minutes View Program |
QSR-Compliant Equipment Control & Validation of Processes in the Manufacturing Environment
Get Instant Access 90 Minutes View Program |
Good Laboratory Practices (GLPS) Comparing and Contrasting With Good Manufacturing Practices (GMPS)
Get Instant Access 90 Minutes View Program |
Methods for Detecting Mycoplasma Contamination In The Manufacture Of Pharmaceuticals and Biologics
Get Instant Access 90 Minutes View Program |
Bioavailability and Bioequivalence Studies submitted in NDAs and INDs
Get Instant Access 90 Minutes View Program |
Get Instant Access On-Demand Access
Preparing for the ICE Storm: What to Do During I 9 Audits and ICE Raids
Janette S. Levey
Human Resources
Get Instant Access On-Demand Access
OSHA Inspections and Investigations-How to Manage Them
Irwin Dobrushin
Environment Health and Safety | OSHA
Get Instant Access On-Demand Access
29 CFR 1904: OSHA's New Injury Recordkeeping E-Submission Rule
Occupational Safety and Health Administration
Get Instant Access On-Demand Access
Working with Excel Databases: Sort, Filter, Subtotal and More
Cathy Horwitz
Cross Industry | Skill Enhancement
Get Instant Access On-Demand Access
Writing Audit Reports
Jonnie T. Keith CIA, CFE, CGAP, CICA
Governance, Risk and Compliance
Get Instant Access On-Demand Access
BSA Reporting Requirements
Banking and Financial Services Industry
Get Instant Access On-Demand Access
Human Factors-Usability Based on ISO 62366
Medical Device | Diagnostic | Pharmaceutical | Biologics fields
Get Instant Access On-Demand Access
Chat GPT for Project Managers
Charles H. Paul
All FDA Regulated Industry